The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
Table 1
Patients baseline characteristics.
Age (years)
72 (43–80)
Sex (male/female)
13 (56)/10 (44)
Diabetes mellitus
6 (26)
Time since diagnosis of MM (months)
1.9 (0–64.4)
Previous lines of treatment
0
11 (48)
One line
11 (48)
VAD
1
BTD followed by MPT
2
High dose dexamethasone
3
Thalidomide + dexamethasone
2
Lenalidomide + dexamethasone
2
Cyclophosphamide + prednisolone
1
Two lines
1 (4)
Melphalan + prednisolone → bortezomib
MM type
IgG
14 (61)
IgA
5 (22)
Light chain
4 (17)
ISS stage
I
8 (35)
II
6 (26)
III
9 (39)
Beta-2-microglobulin (mg/L)
4.6 (2–17.5)
Albumin (g/dL)
3.5 (2.2–4.6)
GFR (mL/min/1.74 m2)
74.3 (15.1–151.7)
Hemoglobin (g/L)
98 (64–130)
White blood cell (×109/L)
4.9 (1.3–8.5)
Platelet (×109/L)
171 (53–408)
Data are median (range) or number (%). GFR was calculated with MDRD equation. MM: multiple myeloma, VAD: vincristine + doxorubicine + dexamethasone, BTD: bortezomib + thalidomide + dexamethasone, MPT: melphalan + prednisolone + thalidomide, ISS: international staging system, and GFR: glomerular filtration rate.
